Advertisement

We need your help now

Support from readers like you keeps The Journal open.

You are visiting us because we have something you value. Independent, unbiased news that tells the truth. Advertising revenue goes some way to support our mission, but this year it has not been enough.

If you've seen value in our reporting, please contribute what you can, so we can continue to produce accurate and meaningful journalism. For everyone who needs it.

File Julien Behal/PA Archive/Press Association Images
BID

Royalty gives up bid for Irish biotech firm Elan

The US intellectual property investor Royalty Pharma said that it received ‘repeated rejections’ from Elan.

US INTELLECTUAL PROPERTY investor Royalty Pharma announced today it has abandoned its bid to take over Irish biotechnology company Elan after repeated rejections by Elan.

Royalty said its $7.9 billion offer had officially elapsed after Elan shareholders backed, by a thin margin, a share repurchase program which Royalty had opposed.

Royalty said it would not seek support from the Irish Takeover Panel to keep its offer alive in the wake of the vote.

“In light of recent developments, we are no longer pursuing the judicial review we had requested,” Pablo Legorreta, Royalty’s chief executive, said in a statement.

On June 10 Dublin-based Elan rejected as “wholly inadequate” Royalty’s latest bid for the company, aimed at getting access to income streams from its portfolio of drugs, including its blockbuster multiple-sclerosis drug Tysabri.

Four days later Elan’s board publicly authorizsed putting the company up for sale, inviting Royalty to participate.

“The Elan Board and management are aligned in maximising the full value potential of the business on behalf of its shareholders,” the company said in a June 14 statement.

- © AFP, 2013

Read: Elan’s Athlone unit to get $1bn in merger deal>

Read: Elan reports first operating profits for nine years>